Clinical outcomes of eyes with diabetic macular edema switched from aflibercept to ranibizumab therapy

Phoebe L. Mellen; Anthony Obeid; Turner D. Wibbelsman; Jason Hsu; Michelle A. Konkoly; Michael R. Velez; Daniel B. Calem; Kareem Sioufi; Thomas L. Jenkins; David Xu; Allen Chiang; Omesh P. Gupta; Marc Spirn; Carl D. Regillo; Allen C. Ho; Michael A. Klufas

doi:10.3928/23258160-20201202-03

Clinical outcomes of eyes with diabetic macular edema switched from aflibercept to ranibizumab therapy

Phoebe L. Mellen, Anthony Obeid, Turner D. Wibbelsman, Jason Hsu, Michelle A. Konkoly, Michael R. Velez, Daniel B. Calem, Kareem Sioufi, Thomas L. Jenkins, David Xu, Allen Chiang, Omesh P. Gupta, Marc Spirn, Carl D. Regillo, Allen C. Ho, Michael A. Klufas

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

BACKGROUND AND OBJECTIVE: In 2018, cases of inflammation were reported after intravitreal aflibercept (IVA), which resulted in switches to intravitreal ranibizumab (IVR). The authors' purpose was to evaluate outcomes after switching from IVA to IVR in diabetic macular edema (DME). PATIENTS AND METHODS: Retrospective cohort study. Eyes switched from IVA to IVR for treating DME were included. Data were gathered from three visits before to three visits post-switch. Outcome measures included central subfoveal thickness (CFT) and Snellen visual acuity (VA). RESULTS: There was a statistically significant increase in CFT at the first visit (325 μm ± 234 μm; P = .006) compared to the switch visit, but no difference later visits (268 μm ± 103 μm; P = .32; 284 μm ± 118 μm; P = .11; n = 54). There was no statistically significant change in mean logarithm of the minimum angle of resolution VA between the switch and later visits (0.43 ± 0.38, P = .95; 0.38 ± 0.30, P = .12; 0.41 ± 0.37, P = .69). CONCLUSIONS: The authors observed transient worsening of macular edema in eyes treated for DME when switched from aflibercept to ranibizumab.

Original language	English
Pages (from-to)	691-697
Number of pages	7
Journal	Ophthalmic Surgery Lasers and Imaging Retina
Volume	51
Issue number	12
DOIs	https://doi.org/10.3928/23258160-20201202-03
State	Published - Dec 2020
Externally published	Yes

Access to Document

10.3928/23258160-20201202-03

Cite this

Mellen, P. L., Obeid, A., Wibbelsman, T. D., Hsu, J., Konkoly, M. A., Velez, M. R., Calem, D. B., Sioufi, K., Jenkins, T. L., Xu, D., Chiang, A., Gupta, O. P., Spirn, M., Regillo, C. D., Ho, A. C., & Klufas, M. A. (2020). Clinical outcomes of eyes with diabetic macular edema switched from aflibercept to ranibizumab therapy. Ophthalmic Surgery Lasers and Imaging Retina, 51(12), 691-697. https://doi.org/10.3928/23258160-20201202-03

@article{73edb4e85e2549ad87d50c537c9d1c2c,

title = "Clinical outcomes of eyes with diabetic macular edema switched from aflibercept to ranibizumab therapy",

abstract = "BACKGROUND AND OBJECTIVE: In 2018, cases of inflammation were reported after intravitreal aflibercept (IVA), which resulted in switches to intravitreal ranibizumab (IVR). The authors' purpose was to evaluate outcomes after switching from IVA to IVR in diabetic macular edema (DME). PATIENTS AND METHODS: Retrospective cohort study. Eyes switched from IVA to IVR for treating DME were included. Data were gathered from three visits before to three visits post-switch. Outcome measures included central subfoveal thickness (CFT) and Snellen visual acuity (VA). RESULTS: There was a statistically significant increase in CFT at the first visit (325 μm ± 234 μm; P = .006) compared to the switch visit, but no difference later visits (268 μm ± 103 μm; P = .32; 284 μm ± 118 μm; P = .11; n = 54). There was no statistically significant change in mean logarithm of the minimum angle of resolution VA between the switch and later visits (0.43 ± 0.38, P = .95; 0.38 ± 0.30, P = .12; 0.41 ± 0.37, P = .69). CONCLUSIONS: The authors observed transient worsening of macular edema in eyes treated for DME when switched from aflibercept to ranibizumab.",

author = "Mellen, {Phoebe L.} and Anthony Obeid and Wibbelsman, {Turner D.} and Jason Hsu and Konkoly, {Michelle A.} and Velez, {Michael R.} and Calem, {Daniel B.} and Kareem Sioufi and Jenkins, {Thomas L.} and David Xu and Allen Chiang and Gupta, {Omesh P.} and Marc Spirn and Regillo, {Carl D.} and Ho, {Allen C.} and Klufas, {Michael A.}",

year = "2020",

month = dec,

doi = "10.3928/23258160-20201202-03",

language = "English",

volume = "51",

pages = "691--697",

journal = "Ophthalmic Surgery Lasers and Imaging Retina",

issn = "2325-8160",

publisher = "Slack Incorporated",

number = "12",

}

Mellen, PL, Obeid, A, Wibbelsman, TD, Hsu, J, Konkoly, MA, Velez, MR, Calem, DB, Sioufi, K, Jenkins, TL, Xu, D, Chiang, A, Gupta, OP, Spirn, M, Regillo, CD, Ho, AC & Klufas, MA 2020, 'Clinical outcomes of eyes with diabetic macular edema switched from aflibercept to ranibizumab therapy', Ophthalmic Surgery Lasers and Imaging Retina, vol. 51, no. 12, pp. 691-697. https://doi.org/10.3928/23258160-20201202-03

TY - JOUR

T1 - Clinical outcomes of eyes with diabetic macular edema switched from aflibercept to ranibizumab therapy

AU - Mellen, Phoebe L.

AU - Obeid, Anthony

AU - Wibbelsman, Turner D.

AU - Hsu, Jason

AU - Konkoly, Michelle A.

AU - Velez, Michael R.

AU - Calem, Daniel B.

AU - Sioufi, Kareem

AU - Jenkins, Thomas L.

AU - Xu, David

AU - Chiang, Allen

AU - Gupta, Omesh P.

AU - Spirn, Marc

AU - Regillo, Carl D.

AU - Ho, Allen C.

AU - Klufas, Michael A.

PY - 2020/12

Y1 - 2020/12

N2 - BACKGROUND AND OBJECTIVE: In 2018, cases of inflammation were reported after intravitreal aflibercept (IVA), which resulted in switches to intravitreal ranibizumab (IVR). The authors' purpose was to evaluate outcomes after switching from IVA to IVR in diabetic macular edema (DME). PATIENTS AND METHODS: Retrospective cohort study. Eyes switched from IVA to IVR for treating DME were included. Data were gathered from three visits before to three visits post-switch. Outcome measures included central subfoveal thickness (CFT) and Snellen visual acuity (VA). RESULTS: There was a statistically significant increase in CFT at the first visit (325 μm ± 234 μm; P = .006) compared to the switch visit, but no difference later visits (268 μm ± 103 μm; P = .32; 284 μm ± 118 μm; P = .11; n = 54). There was no statistically significant change in mean logarithm of the minimum angle of resolution VA between the switch and later visits (0.43 ± 0.38, P = .95; 0.38 ± 0.30, P = .12; 0.41 ± 0.37, P = .69). CONCLUSIONS: The authors observed transient worsening of macular edema in eyes treated for DME when switched from aflibercept to ranibizumab.

AB - BACKGROUND AND OBJECTIVE: In 2018, cases of inflammation were reported after intravitreal aflibercept (IVA), which resulted in switches to intravitreal ranibizumab (IVR). The authors' purpose was to evaluate outcomes after switching from IVA to IVR in diabetic macular edema (DME). PATIENTS AND METHODS: Retrospective cohort study. Eyes switched from IVA to IVR for treating DME were included. Data were gathered from three visits before to three visits post-switch. Outcome measures included central subfoveal thickness (CFT) and Snellen visual acuity (VA). RESULTS: There was a statistically significant increase in CFT at the first visit (325 μm ± 234 μm; P = .006) compared to the switch visit, but no difference later visits (268 μm ± 103 μm; P = .32; 284 μm ± 118 μm; P = .11; n = 54). There was no statistically significant change in mean logarithm of the minimum angle of resolution VA between the switch and later visits (0.43 ± 0.38, P = .95; 0.38 ± 0.30, P = .12; 0.41 ± 0.37, P = .69). CONCLUSIONS: The authors observed transient worsening of macular edema in eyes treated for DME when switched from aflibercept to ranibizumab.

UR - http://www.scopus.com/inward/record.url?scp=85098744067&partnerID=8YFLogxK

U2 - 10.3928/23258160-20201202-03

DO - 10.3928/23258160-20201202-03

M3 - Article

C2 - 33339050

AN - SCOPUS:85098744067

SN - 2325-8160

VL - 51

SP - 691

EP - 697

JO - Ophthalmic Surgery Lasers and Imaging Retina

JF - Ophthalmic Surgery Lasers and Imaging Retina

IS - 12

ER -

Clinical outcomes of eyes with diabetic macular edema switched from aflibercept to ranibizumab therapy

Abstract

Access to Document

Fingerprint

Cite this